Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Price Target of $56.00

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) has earned an average rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $53.00.

Several equities analysts have commented on KRSA shares. TD Cowen initiated coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating on the stock. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. Stifel Nicolaus started coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They set a “buy” rating and a $43.00 price target for the company. Wall Street Zen raised Cyclerion Therapeutics to a “sell” rating in a report on Saturday. Finally, UBS Group assumed coverage on Cyclerion Therapeutics in a report on Friday, September 11th. They set a “buy” rating and a $55.00 price objective on the stock.

Cyclerion Therapeutics Price Performance

KRSA stock opened at $30.72 on Friday. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36. The firm has a market capitalization of $20.58 million, a P/E ratio of -2.64 and a beta of 1.72.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.